Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study.
Gabriele SebastianelliFrancesco CasilloAntonio Di RenzoChiara AbagnaleEttore CioffiVincenzo ParisiCherubino Di LorenzoMariano SerraoFrancesco PierelliJean SchoenenGianluca CoppolaPublished in: Toxins (2023)
(1) Background: OnabotulinumtoxinA (BoNT-A) is a commonly used prophylactic treatment for chronic migraine (CM). Although randomized placebo studies have shown its clinical efficacy, the mechanisms by which it exerts its therapeutic effect are still incompletely understood and debated. (2) Methods: We studied in 15 CM patients the cephalic and extracephalic nociceptive and lemniscal sensory systems using electrophysiological techniques before and 1 and 3 months after one session of pericranial BoNT-A injections according to the PREEMPT protocol. We recorded the nociceptive blink reflex (nBR), the trigemino-cervical reflex (nTCR), the pain-related cortical evoked potential (PREP), and the upper limb somatosensory evoked potential (SSEP). (3) Results: Three months after a single session of prophylactic therapy with BoNT-A in CM patients, we found (a) an increase in the homolateral and contralateral nBR AUC, (b) an enhancement of the contralateral nBR AUC habituation slope and the nTCR habituation slope, (c) a decrease in PREP N-P 1st and 2nd amplitude block, and (d) no effect on SSEPs. (4) Conclusions: Our study provides electrophysiological evidence for the ability of a single session of BoNT-A injections to exert a neuromodulatory effect at the level of trigeminal system through a reduction in input from meningeal and other trigeminovascular nociceptors. Moreover, by reducing activity in cortical pain processing areas, BoNT-A restores normal functioning of the descending pain modulation systems.
Keyphrases
- neuropathic pain
- end stage renal disease
- chronic pain
- ejection fraction
- transcranial direct current stimulation
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- upper limb
- pain management
- prognostic factors
- botulinum toxin
- high intensity
- spinal cord injury
- clinical trial
- men who have sex with men
- patient reported outcomes
- open label
- phase iii
- ultrasound guided
- mesenchymal stem cells
- phase ii
- patient reported
- replacement therapy